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ABSTRACT
Introduction: Atrial fibrillation affects almost 2% of
the population in the Western world. To preserve sinus
rhythm, ablation is undertaken in symptomatic
patients. Observational studies show that patients with
atrial fibrillation often report a low quality of life and
are less prone to be physically active due to fear of
triggering fibrillation. Small trials indicate that exercise
training has a positive effect on exercise capacity and
mental health, and both patients with recurrent atrial
fibrillation and in sinus rhythm may benefit from
rehabilitation in managing life after ablation. No
randomised trials have been published on cardiac
rehabilitation for atrial fibrillation patients treated with
ablation that includes exercise and psychoeducational
components.
Aim: To test the effects of an integrated cardiac
rehabilitation programme versus treatment as
usual for patients with atrial fibrillation treated with
ablation.
Methods and analysis design: The trial is a
multicentre parallel arm design with 1:1 randomisation
to the intervention and control group with blinded
outcome assessment. 210 patients treated for atrial
fibrillation with radiofrequency ablation will be
included. The intervention consists of a rehabilitation
programme including four psychoeducative
consultations with a specially trained nurse and
12 weeks of individualised exercise training, plus the
standard medical follow-up. Patients in the control
group will receive the standard medical follow-up. The
primary outcome measure is exercise capacity
measured by the VO2 peak. The secondary outcome
measure is self-rated mental health measured by the
Short Form 36 questionnaire. Postintervention,
qualitative interviews will be conducted in 10% of the
intervention group.
Ethics and dissemination: The protocol is approved
by the regional research ethics committee (number
H-1-2011-135), the Danish Data Protection Agency
(reg. nr. 2007-58-0015) and follows the latest version
of the Declaration of Helsinki. The results will be
published in peer-reviewed journals and may possibly
impact on rehabilitation guidelines.
Trial registration: Clinicaltrials.gov identifier:
NCT01523145.
ARTICLE SUMMARY
Article focus
▪ The CopenHeartRFA trial is a randomised clinical
trial investigating the effects of comprehensive
cardiac rehabilitation versus usual care for
patients treated for atrial fibrillation (AF) with
ablation.
▪ The hypothesis is that comprehensive cardiac
rehabilitation improves physical capacity and
mental health.
▪ Using a mixed methods approach, a broad range
of outcome measures are collected to evaluate
the intervention.
Key messages
▪ AF affects 1–2% of the population. Patients with
AF experience a diminished quality of life and are
afraid to do physical exercise after treatment with
ablation.
▪ No studies exploring the effects of rehabilitation
of patients treated for AF with ablation have been
published.
▪ This trial is the first to examine physical func-
tioning and to test a comprehensive rehabilitation
programme on a large population of patients
treated for AF with ablation. CopenHeartRFA will
provide much needed evidence and insight on
the postdischarge status and rehabilitation needs
of patients treated for AF with ablation.
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INTRODUCTION
Atrial ﬁbrillation (AF) is the most common sustained
arrhythmia and affects 2% of the population in the
Western world.1–3 Typical symptoms are palpitations, dys-
pnoea, fatigue, dizziness and syncope. Patients’ symp-
toms and the length of periods in AF are highly variable
both for the individual and between patients.4–6 AF is
associated with increased risk of stroke, other thrombo-
embolic events and heart failure.6–8 Hospitalisations due
to AF account for one-third of all admissions for cardiac
arrhythmias.8 As the prevalence of AF increases with
age, the incidence of AF is increasing due to an ageing
population.2 9 10 After 40 years of age, the lifetime risk
of developing AF is 25%.11 The annual cost of AF is
high in comparison with other diseases.12 Therefore, AF
has become an economic burden that will continue to
increase over the coming decades.13 Thus, AF has now
become a health, social and economic challenge in the
Western world.14
Primary treatment goals for individuals with AF are
re-establishing and maintaining sinus rhythm, decreasing
AF symptoms and preventing complications. In accord-
ance with current national and international guidelines,
radiofrequency ablation (RFA) is often undertaken in
symptomatic patients. RFA is an invasive treatment,
intended to cure AF, and has a success rate of 77% versus
52% for antiarrhythmic medication.15 In Denmark,
around 600 RFAs are conducted annually at two heart
centres.
A cohort study of 655 patients from a randomised trial
found that AF symptoms are a negative predictor for
patients’ physical capacity,16 and in the presence of AF,
patients do fewer physical activities.17 Smaller observa-
tional studies and a randomised trial investigating the
effect of exercise training on AF patients found
increased exercise capacity and a decreased resting
heart rate after training.18–20
Previous studies show a signiﬁcantly impaired quality of
life in patients with AF compared with healthy controls
measured by the questionnaire Short Form 36 (SF-36).
The general health component (±SD) was 54±21 in AF
patients compared with 78±17 in healthy controls.21
A qualitative study demonstrated that educational help
after AF treatment is lacking, even though symptoms of
distress and lack of self-management regarding symptoms
like palpitations, dyspnoea and fatigue are common.22
Furthermore, small observational studies indicate a
positive effect of exercise training on patients with AF
in terms of mental health and physical activity (15%
increase of VO2).
18 19 However, these ﬁndings need
conﬁrmation in larger randomised clinical trials.
Secondary prevention initiatives including cardiac
rehabilitation are recommended by the European
Society of Cardiology (ESC).23 Studies exploring the
effects of rehabilitation for patients treated for AF are
lacking. As there is no evidence of its efﬁcacy, rehabilita-
tion is not systematically provided in Denmark and most
often patients treated for AF with RFA are not offered
any rehabilitation at all. The evidence for general
cardiac rehabilitation is strong, but it is found that it is
poorly implemented and only selected patient groups
are offered full comprehensive cardiac rehabilitation
programmes, even though ESC recommends such pro-
grammes.24 Research has mainly been conducted within
patients with coronary heart disease and heart failure,
where rehabilitation has been proven to reduce hospital
readmissions and mortality in a cost-effective way,25 26 as
well as to improve the quality of life.27 More speciﬁcally,
studies on the effect of exercise training have demon-
strated an increase in exercise capacity of up to 38% in
patients after valve replacement surgery28 and an increase
in peak VO2 of 2.3±2.2 (SD) ml/kg/min in the interven-
tion group compared with −0.3±2.1 (SD) ml/kg/min in
the control group, as well as a signiﬁcant change in the
quality of life in older patients with heart failure.29
Traditional cardiac rehabilitation has focused on phys-
ical training and standardised programmes, but studies
now indicate that individualised content and supervised
exercise components can improve outcomes.30 In add-
ition to exercise training, there is evidence to support
interventions that include patient education, which in
patients with coronary heart disease has shown to
improve health-related quality of life and decrease health-
care costs31 and psychological support, which has been
shown to improve psychological symptoms, such as
depression and anxiety.32 Interventions designed to cover
both physical and psychological problems may provide
the best method for optimising functioning and enhan-
cing the quality of life.33 We have not been able to iden-
tify randomised trials or observational studies in patients
who have undergone RFA for AF that offer both psychoe-
ducational intervention and physical training. Therefore,
the CopenHeartRFA trial was undertaken with the aim of
testing a rehabilitation programme consisting of physical
exercise and a psychoeducational intervention versus
treatment as usual for RFA-treated AF patients.
METHODS
Design
Major parts of the method section and trial design in
this paper are similar to two other randomised clinical
trials, CopenHeartVR and CopenHeartIE, and therefore
ARTICLE SUMMARY
Strengths and limitations of this study
▪ The study has been designed to meet the criteria for high
quality in non-pharmacological randomised clinical trials with
central randomisation, multicentre participation, blinded
assessment and analysis.
▪ We are aware of the day-to-day variation that can appear when
carrying out ergospirometry in testing and that the perform-
ance can depend on the individual tester. Accordingly, we will
interpret the findings conservatively.
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sections from this paper will be copied in these trial pro-
tocols (Sibilitz KL et al Effect of integrated cardiac rehabilita-
tion vs treatment as usual for patients with isolated heart valve
surgery: the randomised CopenHeart valvular trial protocol
drafted October 2012 and Rasmussen et al34).
The CopenHeartRFA trial is a multicentre, multidisciplin-
ary randomised clinical superiority trial. Secondary quali-
tative data are also collected and the two methods are
integrated by applying a mixed-method-embedded experi-
mental design (ﬁgure 1).35 36 Quantitative methods are
applied, with speciﬁed quantitative premeasures and post-
measures, to evaluate the effect of the experimental inter-
vention. Alongside quantitative measurements, qualitative
data will be collected. The premise of mixed methods
research is that the use of qualitative and quantitative
approaches in combination provides a better understand-
ing of the research problems than either approach alone,
because different types of questions require different types
of data and mixed methods research provides strengths
that offset the weaknesses of both qualitative and quantita-
tive research.34 The methods are integrated by applying a
mixed-method-embedded experimental design and
include qualitative data to develop the intervention and to
examine the process of the intervention and the results of
the trial (see ﬁgure 1).35 36 The rationale for this approach
is that the quantitative ﬁndings provide a general under-
standing of the research problem through statistical
results, whereas the qualitative ﬁndings reﬁne and explain
the results by exploring participants’ views in greater detail
and will be presented by themes of patient thoughts or
concerns about the intervention. Evaluation using qualita-
tive research methods is increasingly promoted in
evidence-based rehabilitation.37–40 Qualitative research
alongside randomised controlled trials can contribute in
several ways to the development and evaluation of
complex healthcare interventions and may be particularly
useful in evaluating interventions that involve social and
behavioural processes that are difﬁcult to explore or
capture using quantitative methods alone.41 As patient par-
ticipation is paramount for the efﬁcacy of the rehabilita-
tion,42 we ﬁnd it highly valuable to include the patients’
perspective in the development and evaluation of the
intervention. This paper presents the study protocol for
the CopenHeartRFA randomised clinical trial. The comple-
mentary studies, including the qualitative part of the trial,
are brieﬂy described in a separate section.
The trial is described in accordance with the current
SPIRIT guidelines (Standard Protocol Items:
Recommendations for Interventional Trials).43 Results will
be reported following the CONSORT (CONsolidated
Standards Of Reporting Trials) guidelines for non-
pharmacological interventions.44
Trial hypotheses
The primary hypothesis is that the rehabilitation pro-
gramme increases physical capacity among AF patients
treated with RFA after 4 months, measured by the VO2
peak, which is expected to be 20% more than in the
control group receiving standard treatment alone. The
estimate of 20% is based on ﬁndings from pilot studies
including patients with permanent AF which found an
increase of 15% in the VO2 peak. We therefore expect a
VO2 peak in the intervention group of 18 and of 15 ml/
kg/min in the control group, corresponding to a differ-
ence of 20% (3 ml/kg/min).45
The secondary hypothesis is that the rehabilitation
programme increases the quality of life and self-rated
mental health among AF patients treated with RFA after
6 months by three points on the Medical Outcome
Study SF-36 questionnaire mental component scale,
compared with control participants receiving standard
treatment.19
Exploratory hypotheses are that the experimental
intervention decreases AF recurrence; improves self-
rated health and sleep-quality; reduces early retirement
from work, use of healthcare services and mortality, and
is cost efﬁcient.
Trial participants
Consecutive patients hospitalised for AF and treated
with RFA at two heart centres in Denmark (Gentofte
Hospital and Rigshospitalet, Copenhagen University
Hospital) will be screened for inclusion and approached
for trial participation (ﬁgure 2). Regardless of the RFA
outcome, both patients with recurrent AF and patients
in sinus rhythm after the ablation will be included in the
trial. Patients 18 years of age or older, Danish speaking
and providing verbal and written informed consent will
be eligible for participation. Patients unable to under-
stand trial instructions, pregnant or breastfeeding, with
reduced ability to follow the planned programme due to
other physical illness, who prior to RFA have been doing
intense physical exercise or sports at a competitive level
several times a week, or who do not wish to participate
and patients already enrolled in clinical trials that pro-
hibit participation in additional trials are excluded.
Trial procedure, randomisation and follow-up
Patients will be approached for participation during
their hospitalisation for RFA. Information will be given
by a nurse or physician from the research team, who will
obtain written informed consent after the RFA proced-
ure. A brief oral introduction is initially given together
with written information describing the trial and
Figure 1 The CopenHeartRFA trial. Mixed methods research
design. Embedded Experimental Model. QUAN, quantitative
data, QUAL, qualitative data.
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implications for the patient in detail. The patient is
given ample time to read the information and, if neces-
sary, involve a relative in the decision-making. The enrol-
ling nurse or physician will return after the RFA or call
the patient to answer any questions that the patient or
their relative might have. The patient should subse-
quently be able to provide informed consent or reject
participation. After the informed consent form is
signed, baseline data will be collected including the
baseline questionnaire package, demographic variables
and clinical characteristics (table 1).
Then the Copenhagen Trial Unit (http://www.ctu.dk/)
is contacted for central randomisation of the participant.
Randomisation is conducted according to a computer-
generated allocation sequence with a varying block size
kept unknown to the investigators. Participants are rando-
mised 1:1 to the experimental intervention group or the
control group and stratiﬁed according to sex and type of
AF (persistent or paroxysmal). Thus, neither the investiga-
tors nor the patients or relatives can inﬂuence the group
to which the patients are allocated. For both groups, the
follow-up assessment will take place at 1, 4, 6 and
12 months postdischarge, and a register-based follow-up
assessment will be conducted at 24 months (table 1). In
case of complications to the RFA after enrolment in the
trial, the patients will be handled individually (eg, arrhyth-
mia or inguinal haematoma).
The patients answer questionnaires independently of
the researchers, and before randomisation. All question-
naires are distributed electronically; thus, data
management is handled independently from the
researchers who interpret the data. All data are stored
electronically in a coded database, and in an independ-
ent spreadsheet, accessible only to the CopenHeart
group.
Personal information about the potential and enrolled
patients will be collected electronically and shared in a
database accessible only to those within the project
group responsible for patient recruitment, in order to
protect conﬁdentiality before, during and after the trial.
Owing to the nature of rehabilitation, the intervention
group is not blinded to the patients or the investigators,
but the outcome assessment of the primary outcome,
the statistical analyses and drawing of conclusions will be
conducted blinded to the allocated intervention group.
Experimental intervention group
Patients in the experimental intervention group will
follow the integrated cardiac rehabilitation programme
consisting of a psychoeducational component and an
exercise training component alongside standard treat-
ment (described below). The patients will be contacted
at 1, 4, 6 and 12 months for outcome assessment includ-
ing clinical data collection.
Physical exercise training component
The intervention has been developed and partly tested
in a clinical rehabilitation trial, the COPE-ICD trial,60
which included patients with an implantable cardiover-
ter deﬁbrillator (ICD). Here, we observed a signiﬁcant
Figure 2 The flow of patients through the trial.
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impact of the intervention on peak VO2, physical cap-
acity and self-assessed mental health. The intervention
has been modiﬁed for patients treated for AF with abla-
tion as described below. The CopenHeart physical exer-
cise intervention meets European24 and Danish
guidelines61 for physical exercise in patients with heart
disease, and complies with The National Danish Board
of Health recommendations for physical exercise in
daily living for heart patients.62
The physical exercise starts 1 month after ablation and
after the ﬁrst ergospirometry test and comprises the fol-
lowing three elements:
Individually planned physical exercise by specially trained
physiotherapists
Integrating detailed information concerning the AF
symptoms and RFA, comorbidity, hospitalisation, activ-
ities of daily living and level of physical activity prior to
RFA, a specially trained physiotherapist conducts a
patient telephone consultation up to 30 min. The con-
sultation is based on initial testing of the patient includ-
ing a cardiopulmonary exercise test, a 6-min walking test
and a ‘sit to stand’ test, described in the outcome
section. For all patients, a rehabilitation plan is prepared
as an individual training diary, and all patients are
instructed in the use of a heart rate monitor (Polar
Watch provided by Rigshospitalet). The heart rate
monitor and diary are essential to ensure CopenHeart
training protocol compliance, and they are returned for
data collection at the end of the exercise training
intervention.
Intensive exercise training programme
Physical exercise is initiated at Rigshospitalet 4 weeks
after RFA to ensure optimal rest and healing. Using wire-
less electrodes integrated into T-shirts (Corus-Fit,
Table 1 Exploratory quantities subjected to post hoc analysis
Quantity Time of measure (months) Type of quantity
Demographic
Sex BL Binary (M/F)
Age, height, weight BL, 1, 4, 12 Continuous
Marital, occupational, educational status BL Categorical
Clinical
NYHA classification BL, 1, 4, 12 Continuous
Previous heart disease, diabetes mellitus, kidney disease,
pulmonary disease (COPD), comorbidities, hypertension,
dyslipidaemia, smoking
BL Binary (Y/N)
Medication BL, 1, 4, 12 Binary (Y/N)
AF specific data
Type of atrial fibrillation BL Categorical
Number of ablations BL, 1, 4, 12 Binary (Y/N)
Atrial fibrillation symptoms BL, 1, 4, 12 Continuous
CHA2DS2VASc score BL, 1, 4, 12 Continuous
The European Heart Rhythm Association symptom score BL, 1, 4, 12 Continuous
Paraclinical and imaging
Blood work (Haemoglobin, potassium, sodium, creatine, pro-BNP,
BNP and copeptin)
BL, 1, 4, 12 Continuous
Electrocardiogram BL, 4, 12 Continuous
Physical function
6 min walking test46 BL, 1, 4, 12 Continuous
Sit to stand test47 1, 4, 12 Continuous
EVO recording 1, 4, 12 Categorical
Questionnaires
Physical activity level48 BL, 1, 4, 6, 12, 24 Binary (Y/N)
SF-3649 HADS,50 QoL-CV51 BL, 1, 4, 6, 12, 24 Continuous
Emotions and Health52 BL Continuous
Rehabilitation53 12 Continuous
HeartQoL R,54 EQ-5D55 BL, 6, 12, 24 Continuous
IPAQ56 1, 4, 12, 24 Continuous
PSQI58 1, 6 Continuous
AFEQT59 BL, 1, 4, 12, 24 Continuous
AFEQT, Atrial Fibrillation Effect on Quality-of-life; BL, baseline; CHA2DS2VASc, score for Atrial Fibrillation Stroke Risk; EQ-5D, EuroQoL;
HADS, Hospital Anxiety and Depression Scale; HeartQoL R, Heart-Related Quality of Life; IPAQ, International Physical Activity Questionnaire;
PSQI, Pittsburgh Sleep Quality Index; QoL-CV, Quality of Life—Cardiac Version; SF-36, Short Form 36.
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CardioCardio and Corus Exercise Assistant, CEA,
V.2.0.16, Finland), potential cardiac arrhythmias, ECG
abnormalities such as ST depression, ST elevation,
Q wave or T wave altering, AF and ventricular arrhyth-
mias and training intensity level are monitored.
After 1–3 exercise training sessions at Rigshospitalet,
the patient continues the programme at a local
CopenHeart certiﬁed training facility supervised by phy-
siotherapists or as supervised home-based training.
Supervised home-based exercise training has shown
similar results to hospital-based exercise training31 and
has been conﬁrmed in a Danish setting.63
The physical exercise training continues for 12 weeks,
comprising three weekly sessions of 60 min each, in
total, 36 sessions. The training protocol consists of car-
diovascular training and strength exercises to improve
endurance and muscular strength.
An exercise session consists of 10 min warm-up,
20 min bicycling, 20 min strength and a 10 min stretch-
ing and cool-down period. Using the results from the
cardiopulmonary exercise test performed prior to the
initial training session, in combination with the Borg
Scale measuring subjective exhaustion, the aerobic exer-
cise is performed with gradually increasing intensity
throughout the exercise intervention period, corre-
sponding to 13–17 on the Borg Scale and 50–80% of
the maximum heart rate. The anaerobic resistance train-
ing is initiated at 30–40% of one repetition maximum
(RM) for the upper body and 40–50% of one RM for
the lower body, with an increasing workload during the
training sessions. To achieve cardiovascular adjustment
and reduce the risk of malignant cardiac arrhythmias
and ischaemia, the training session is initiated and ter-
minated with a warm-up and a cool-down period to grad-
ually increase and decrease the training intensity and
heart rate. This cardiovascular adjustment has been
proven to reduce the risk of ischaemia and arrhythmia
in relation to exercise training.64 65 Training is predom-
inantly performed in the upright position to reduce left
ventricle preload (diastolic volume) and the risk of
ischaemia and arrhythmias due to heart failure.65
Sustained moderate physical exercise daily
Participants are instructed to perform moderate physical
exercise for at least 30 min a day during the intervention
period, for example, bicycling, walking, gardening,
jogging or recreational sports. Participants are encour-
aged to continue with moderate physical exercise
throughout their lives.
Psychoeducational component
The aim of the psychoeducational intervention is to
provide emotional support and improve coping skills
and illness appraisal in order to enable the patient to
respond appropriately to physical and psychological
symptoms. Education and information about the disease
prepare the patient for expected symptoms and sensa-
tions. Dialogue and shared reﬂection facilitate strategies
for coping with symptoms and experiences associated
with the condition, for example, anxiety and fear.
Cardiac care nurses with speciﬁc training will perform
the psychoeducational intervention. Some of the most
commonly reported concerns of patients treated for AF
with RFA, such as recurrent AF, and concerns about
being able to manage a working life are outlined in a
guide which nurses use to address when and if relevant
(see table 2). The information given will also be based
on the national guidelines and standard treatment of
patients treated for AF. The consultations focus on man-
aging life after AF treated with RFA by establishing a
joint approach to disease management and coping strat-
egies, taking a holistic view. The psychoeducational inter-
vention is inspired by R.R. Parse’s Human Becoming
Practice Methodologies’ three dimensions.66 These are
Table 2 Guide to the psychoeducative consultation
Number visit 1 2 3 4
Ask the patient how he/she has been since the ablation. What has happened since
the last time he/she was here?
X X X X
Invite the patient to talk about his/her thoughts and questions X X X X
Ask about the time leading up to RFA and his/her AF history. Experiences before,
under and after the hospitalisation and RFA
X
Talk about how it is to have had/have AF and been through RFA, how that affected
the patient’s life. Is there something he/she avoids or feels like he/she cannot do
anymore? This is in relation to family relations, friends and free time/leisure activities
X
Make sure that the patient has started the physical training and talk about how it is
going. Are training appointments booked?
X X X
Talk about if the patient has changed his/her feelings or thoughts of the body and its
functions
X
Talk about recognition of symptoms, how the patient is feeling about the recurrence
of AF and opinions about future AF treatment. Worries about the recurrence of AF,
strategies of prevention
X X (X) (X)
Information/recommendations in relation to the subjects/problems discussed X X X X
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interpreted as: (1) to discuss and give meaning to the
past, present and future, (2) to explore and discuss
events and possibilities and (3) to move along with envi-
sioned possibilities. According to this theory, there are
three ways of changing health: creative imaging, that is
to see, hear and feel what a situation might be like if
lived in a different way, afﬁrming personal patterns and
value priorities and shedding light on paradoxes, that is,
looking at the incongruence in a situation and changing
the view held of something. The nurse is present in the
process through discussions, silent immersion and reﬂec-
tion. The human becoming practice methodology was
chosen to apply a holistic patient approach, focusing on
the coping and transformation process of the individual
person. Furthermore, the method is already extensively
used in the outpatient heart clinics at the heart centre
at Rigshospitalet, such as for patients with inherited
heart diseases and adults with congenital heart disease,
and is documented in the COPE-ICD trial.60 67 The con-
sultations take place in a quiet setting at the outpatient
clinic and will last for approximately 1 h. The nurse is
able to facilitate contact with or seek advice from a phys-
ician if needed. The ﬁrst consultation will be approxi-
mately 1 month after discharge, and then once every
4–6 weeks, with a total of four consultations.
Consultations can be done by telephone, in accordance
with the patient’s wishes. The primary investigator will
attend the consultations regularly to ensure protocol
compliance.
Intervention deviations
Both components of the intervention will be supervised
regularly by the primary investigator to ensure protocol
compliance. Modiﬁcation of the allocated intervention
due to surgery complications, rehospitalisation or emer-
ging comorbidities (eg, recurrent AF and musculoskel-
etal problems) will be individually assessed, and the time
of the primary outcome assessment at 4 months
(described in section below) will be corrected in accord-
ance with changes in the intervention.
Control group: treatment as usual
Patients in the control group will follow standard treat-
ment for patients treated for AF with RFA including a
3–6-month follow-up with a physician and a 12-month
follow-up with a nurse. Furthermore, patients will be
contacted at 1, 4, 6 and 12 months for outcome assess-
ment including clinical data collection.
Outcomes and data collection
Data will be collected to evaluate the effect and
meaning of the intervention. The primary and second-
ary outcomes reﬂect the primary modiﬁable factors of
the intervention. Since this is a complex intervention
with two main components, an exercise component and
a psychoeducational component, this is reﬂected in the
primary and secondary outcomes. The intervention has
been tested in ICD patients (unpublished data in the
COPE-ICD trail, available on request) and reﬂects well
in the chosen measures that have been found to be sen-
sitive to changes based on the intervention. Since almost
no evidence exists for rehabilitation programmes for
patients treated for AF with RFA, data on a number of
outcomes will be collected for exploratory analyses.
Primary outcome
Physical capacity is measured by peak VO2 according
to a standardised protocol developed in accordance
with the guidelines68 69 1, 4 and 12 months after
randomisation.
Physical capacity is measured by peak VO2 using cardio-
pulmonary exercise testing (Ergo-Spiro CS-200, Schiller,
Schweiz). This is chosen as a primary outcome since this
is standard in exercise-based rehabilitation trails. The test
is performed according to current guidelines for ergos-
pirometry testing, and by an ergometer bicycle, simultan-
eously monitoring heart rhythm, blood pressure, ECG
and measuring gas exchange during workload and in the
following recovery period. The average test duration is
10–15 min including the pretest and post-test phases
without workload. Before each session, calibration is per-
formed to address changes in room temperature, humid-
ity and air oxygen content. A standardised ramp protocol
is used with an initial workload of 25 or 50 watts, increas-
ing gradually by 12.5 W/min until peak exhaustion. Peak
exhaustion is evaluated by a respiratory exchange ratio≥T
1.10 or by subjective exhaustion of the patient. In order
to encourage the patients equally, independent of the
tester, a standardised guide has been developed. During
the test period, clinical manifestations, ECG abnormal-
ities (ST depression, ST elevation, Q wave and T wave
changes, supraventricular or ventricular arrhythmias),
blood pressure response and several physiological
variables are observed and documented. The test will be
performed by either a cardiac care nurse or a physician.
For safety reasons, preset criteria for initiation and/or
termination of the test have been deﬁned.
Secondary outcome
Self-rated mental health is measured by the SF-36 ques-
tionnaire,70–72 mental component score, after 1, 4, 6
and 12 months (table 1).
Exploratory outcomes
Long-term follow-up
Register data regarding mortality, causes of death, hospi-
talisation/rehospitalisation, emergency room visits, out-
patient visits, healthcare costs, visits to the general
practitioner, medication use, employment status and
payment of welfare beneﬁts (sick leave payment and
early retirement pension) will be collected at 24 months
to assess the long-term effects of the intervention (table
1). Danish record keeping for the aforementioned data
functions well, with only a small percentage of lost
data.73 Consequently, the method is well suited as an
outcome measure in small patient populations. Data will
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be extracted from the Danish National Patient Register,
the Danish National Health Service Register, the Danish
National Prescription Registry, the Danish National
Causes of Death Register and records of transfer pay-
ments and labour market afﬁliation.74–77
Six minutes walking test
The maximum walking distance (in metres) within
6 min is measured, using standardised instructions,46
while subjective exhaustion with regard to fatigue and
dyspnoea using the Borg Scale78 is registered.
Sit and stand test
The maximum number of times a patient can sit and
rise from a normal chair within 30 s is recorded.
Subjective exhaustion is measured using the Borg
exhaustion scale.78
Biochemical screening
Potassium, sodium, haemoglobin and creatine. One
EDTA plasma heparin tube will be frozen (80°) for
further analyses (pro-BNP, BNP, copeptin).
Other exploratory outcomes
AF recurrence, self-rated health and sleep-quality, retire-
ment from work, use of healthcare services, mortality
and cost efﬁciency (table 1).
Sample size calculation for the primary outcome
We are performing a randomised trial where the con-
tinuous variable VO2 peak is the primary outcome. The
control and intervention groups are independent, and
the ratio of patients in the intervention group to the
patients in the control group is 1:1. A previous trial of
patients with permanent AF found that the VO2 peak
was normally distributed with an SD of 3.8 ml/kg/min.45
As the CopenHeartRFA trial has a more varied patient
population that has been treated for AF with RFA, which
means that the majority of the patients will have sinus
rhythm and the rest will have AF, the patients are not
directly comparable with the patients in the previous
trial, and we assume an SD of 6 ml/kg/min to be more
relevant. We consider a 0.5 SD to be the minimal rele-
vant difference, equivalent to 3 ml/kg/min. Therefore,
if the true difference between the intervention and
control groups is 3 ml/kg/min and the SD is 6 ml/kg/
min in the control group, 105 patients in the interven-
tion group and 105 in the control group (a total of 210
patients) are needed to reject the null hypothesis,
stating that the mean in the intervention and the
control groups is the same, with a power of 95%. The
type I error probability associated with this test of this
null hypothesis is 5%.
Power calculation for the secondary outcome
The secondary outcome measure is the continuous vari-
able mental component, SF-36. If the true difference
between the intervention and control groups is 7 points,
and the SD in the control group is 18 points,22 we will
be able to reject the null hypothesis that the population
means of the experimental and control groups are equal
with a probability of (power) 0.80. The type I error
probability associated with this test of this null hypoth-
esis is 5%.
Statistical analyses
Data will be pseudoanonymised and analysed blinded by
a trial-independent statistician using intention-to-treat
analyses and a mixed model with repeated measures
(MMRM) for continuous outcome measures.79 Using
MMRM ensures that missing data values (in case of the
primary and secondary outcomes) will not create bias as
long as the values are missing at random. Two-sided tests
are performed. The level of signiﬁcance is set at 5%.
With regard to multiplicity, gate keeping will be used to
adjust the observed p values for primary and secondary
outcomes.80 Both unadjusted and adjusted p values will
be reported.
For the primary and secondary outcomes, sensitivity
analysis will be conducted to assess the potential impact
of values missing not at random. For each intervention
group (A and B), some quantities (imputing quantities)
are computed to be used to impute missing values in a
group (A or B) as follows. A comparison between
groups A and B, where missing values in group A are
imputed using imputing quantities obtained from group
A and missing values from group B are imputed using
imputing quantities obtained from group B, is referred
to as a best case analysis. If missing values in group A
are imputed using imputing quantities obtained from
group B and vice versa, the comparison is called a worst
case analysis. The imputing quantities for the primary
outcome are the group mean at T1 (X1-bar), the group
mean at T4 (X4-bar), the group mean at T6 (X6-bar),
the mean difference between the value measured at T4
and that measured at T1 (δ1) and the mean difference
between the value measured at T6 and that measured at
T4 (δ2). Table 3 explains how the quantities are used to
impute missing values in a group (either the same
group or the other intervention group). If the SE of a
parameter estimate calculated using imputed data is
smaller than that of the corresponding parameter calcu-
lated using complete case data, it is replaced by the
latter SE when the p value is calculated (table 3).
Long-term register-based outcomes will be analysed by
two different models: non-negative count outcomes (eg,
number of contacts with the hospital or number of visits
to general practitioners) will be analysed by a Poisson
model or a zero-inﬂated Poisson model if the number of
zeros are large, and time-to-event data (eg, cause-speciﬁc
mortality and leaving the labour market) will be ana-
lysed with survival methods (Kaplan-Meier estimator and
Cox regression model). Especially for socioeconomic
outcomes, competing risks due to mortality will be con-
sidered if a large proportion of patients die during
follow-up.
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Exploratory data will be analysed using appropriate
statistical methods according to the type of data (see
table 1). SPSS V.17.0 and SAS V.9.3 will be used.
INTERIM ANALYSIS AND DATA MONITORING
SAFETY COMMITTEE
The Data Monitoring Safety Committee (DMSC) works
independently of the funder and has no competing
interests, and consists of two clinicians and a statistician.
The committee is responsible for safeguarding the inter-
ests of trial participants, assessing the safety and efﬁcacy
of the interventions during the trial and for monitoring
the overall conduct of the clinical trial. In line with the
terms of the DMSC charter, one formal interim analysis
meeting will be held to review data relating to treatment
efﬁcacy, participant safety and quality of trial conduct.
The three members of the DMSC will meet when the
12-week follow-up data of about 50% of the trial partici-
pants have been obtained. Any serious adverse events
will be registered as part of the data collection and the
overall number of adverse events will be reported at the
meeting.
Complementary studies
Survey-based study
The postdischarge status of the patients treated with
RFA will be explored through a national survey. The
standardised questionnaires SF-36,49 Hospital Anxiety
and Depression Scale,50 EuroQoL-EQ-5D,51 52 Heart
Related Quality of Life,53 International Physical Activity
Questionnaire54 55 and a questionnaire developed by the
Danish Heart Foundation on the extent and quality of
rehabilitation offered will be sent to patients having
undergone treatment for RFA, 6–12 months post-
discharge. The instruments are all validated and have
good reliability and responsiveness.50 54 56 57 81 82 The
data will provide knowledge on patients’ self-rated
health, quality of life, anxiety and depression, economic
situation and the extent and quality of the rehabilitation
currently received. Patients were identiﬁed through the
National Patient Register74 and questionnaires were sent
out to 608 patients. We anticipate that 25% will decline
participation, leaving an estimated 456 questionnaire
respondents. Data will be anonymised and analysed by
relevant descriptive statistical methods.
Qualitative postintervention study
After the intervention, 10% of the participants from the
intervention group will be strategically chosen for an
interview in order to explore the experiences and pro-
cesses behind the potential effects of the intervention.
The qualitative study will explore patient experiences of
participating in the CopenHeartRFA programme and
investigate which components were meaningful.
To achieve maximum variation, qualiﬁed interviewees
are chosen on the basis of sex, AF type and current
heart rhythm.83 The analysis will be inspired by
Ricoeur’s theory of interpretation consisting of three
levels: naive reading, structured analysis and critical
interpretation and discussion.84
The results will be presented in themes based on
patient experience and evaluation of the intervention.
As an example, we will look for explanations for the
results in physical capacity and mental health as
described by the patients. We are using a mixed-method
approach to explore all aspects of the intervention, but
the qualitative ﬁndings are seen as a complementary
study to the primary randomised clinical trial.
Economic evaluation
An economic evaluation will be conducted alongside the
trial to assess the cost-utility of cardiac rehabilitation
compared with treatment as usual in the study popula-
tion. The economic evaluation will compare the costs to
Table 3 Statistical analysis
Observed pattern in
group B at 1, 4 and 6 months
Imputed value in
group B at 1 month
Imputed value in
group B at 4 month
Imputed value in
group B at 6 months
mis*, mis, mis X1-bar† X4-bar‡ X6-bar§
mis, mis, Y3¶ Y3—(δ1**+δ2††)‡‡ Y3—δ2
mis, Y2, mis Y2—δ1 Y2+δ2
Y1, mis, mis Y1+δ1 Y1+δ1+δ2
Y1, Y2, mis Y2+δ2
Y1, mis, Y3 (Y1+δ1+Y3—δ2)/2
mis, Y2, Y3 Y2—δ-1
Table to explain the use of imputing quantities derived from observed values in a group (group A) to impute missing values in a group (group
B). mis, missing value, X1, value at month 1, X4, value at month 4, X6, value at month 6.
*The value at 4 months is missing in group B.
†Mean of values observed in group A at time 1 month.
‡Mean of values observed in group A at time 4 months.
§Mean of values observed in group A at time 6 months.
¶Observed value in group B at time 6 months.
**The mean of difference between values observed at time 4 months and value observed at time 1 month in group A.
††The mean of difference between value observed at time 6 months and value observed at time 4 months in group A.
‡‡If an imputed value is 0, it is set equal to 0.
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quality-adjusted life years (QALY) and take a societal
perspective, as recommended nationally. QALYs and
costs will be assessed at the end of the intervention,
6 months from randomisation, and later after 24 months
from randomisation using the register-based follow-up.
QALYs will be estimated using the self-completed
EQ-5D instrument, which is a standardised instrument
assessing ﬁve dimensions of self-reported health status
(mobility, self-care, usual activities, pain/discomfort and
anxiety/depression).85 86 The estimated calculations will
be valued using Danish preference weights.87
Information on costs will only include costs that are
expected to differ between the intervention group and
usual care group.55 Costs included in the evaluation are
health costs associated with the rehabilitation pro-
gramme, other healthcare costs (healthcare utilisation
besides rehabilitation), patient costs and costs of prod-
uctivity losses. Information on costs will be collected by a
mixture of activity-based costing, surveys, patient diary
and by the use of public records. Results from the ana-
lysis will be reported as an incremental cost-effectiveness
analysis (ICER). Sensitivity analysis will be conducted to
express uncertainty in the estimates.88 The reporting of
the ICER is presented using Bayesian methods, includ-
ing bootstrapping and as cost-effectiveness acceptability
curves.89
Ethics
The inclusion started in December 2011 and is approved
by the Regional Ethics Committee (number
H-1-2011-135) and the Danish Data Protection Agency
(no. 2007-58-0015). All eligible patients will be informed
about the trial verbally and in writing, and they are
included after informed consent has been obtained. All
data will be handled conﬁdentially and patients ensured
anonymity. The trial complies with the latest Declaration
of Helsinki and is registered at ClinicalTrials.gov
(NCT01523145). An independent international safety
committee monitors the trial. All serious and adverse
events will be registered and reported in accordance
with the safety charter.
Not providing rehabilitation to the control group can
be ethically justiﬁed as current national and inter-
national guidelines give no speciﬁc recommendations
on cardiac rehabilitation for patients treated for AF with
RFA. The scope and quality of rehabilitation offered to
this population is unknown, but suspicions are that gen-
erally no rehabilitation is offered in Denmark. The only
way patients can get supervised exercise training is if
they voluntarily enrol in a programme, for example,
through non-proﬁt organisations. The survey-based com-
plementary study, described previously in this paper, will
hopefully provide more insight into this. In screening
patients for participation, the enrolling nurse or phys-
ician will exclude those with a compelling rehabilitation
need. Furthermore, patients are informed of the study
design before giving their consent, and are free to
decline participation.
DISCUSSION
Owing to the difference in the three patient groups that
are included in the overall CopenHeart trial, patients
treated for infective endocarditis, heart valve surgery
and for AF patients treated with RFA, the intervention
and outcome measures differ slightly, most importantly
in the case of the psychoeducational intervention, which
is longer for patients treated for infective endocarditis
and heart valve surgery, because of the complexity of the
diseases and the longer hospitalisation. Similarly, bio-
chemical markers are chosen differently to address the
various comorbidities of the three diseases and some
disease speciﬁc questionnaires are chosen to capture the
speciﬁc disease-relevant issues.
To our knowledge, no previous randomised clinical
trials or observational studies have been conducted that
focus on integrated cardiac rehabilitation for AF patients
treated with RFA, and therefore it is not known what
effect, if any, rehabilitation has on these patients.
However, in the light of evidence from other groups of
patients with heart disease, a positive effect can be
expected.23 90 91
This trial is different from previous trials because we
apply a comprehensive rehabilitation intervention which
consists of both a physical training component and a psy-
choeducational component. This combination is
hypothesised to strengthen the patient both physically
and mentally even if the patient has AF. Also, we use a
mixed-method approach, which has its strengths in using
both qualitative and quantitative research designs.35
The major strengths of this randomised clinical trial
are that it includes consecutive patients with a reason-
able number of inclusion and exclusion criteria securing
external validity for the results. The trial employs
central, stratiﬁed randomisation which secures against
selection bias.92–94 The primary outcome is assessed
blinded to intervention and so are all statistical analyses,
which should reduce detection and interpretation
bias.92–94 The long-term outcomes are based on data
taken from public registry data, which are also likely to
not include biased reporting of outcomes.
The secondary outcomes of self-rated mental health
are subjective by nature and are likely to be biased.92–94
The patients answer questionnaires independently of
the researchers. Data management is handled independ-
ently of the researchers who interpret data. All question-
naires are distributed electronically. All data entry is
stored electronically in a coded database, and in an
independent spreadsheet, accessible only to the
CopenHeart Group.
The trial limitations include the fact that it is known
from previous rehabilitation trials33 that patients in the
control group have a tendency to do physical training
due to the focus on the subject in the recruitment
process. We will be aware of that when we recruit and
not focus on giving extensive information about the
exercise programme, or encourage patients to do phys-
ical training before knowing which group they are
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randomised to. Any difference between patients com-
pleting the intervention and those not completing
(dropouts) will be carefully discussed when evaluating
the intervention, results and the suitability for imple-
mentation. The trial is designed with multiple statistical
comparisons, so results will be interpreted with caution.
Further limitations of the trial and methods used are
similar to those of other trials including physical exer-
cise and physical testing, namely time-of-day and
day-to-day variation using exercise testing.95 To ensure
standard testing of all physical exercise tests in the trial,
standardised instructions for patients have been devel-
oped as described in the methods section. Conversely,
the trial population will be representative of the true
RFA population, meaning that some patients will have
AF and some sinus rhythm while exercising and testing,
and this will facilitate implementation of The
CopenHeartRFA trial rehabilitation programme in daily
clinical practice. We are aware that patients treated with
RFA are a highly select group of patients with paroxys-
mal or persistent AF, and they are more likely to partici-
pate properly and complete a rehabilitation programme,
compared with patients with, for example, permanent
AF, since patients with permanent AF are often older
and suffer from comorbidity.4 Therefore we do not
expect to generalise the results to all AF patients.
The challenge with the set-up is that patients come
from considerable distances, and therefore some will
decline participation. Also, owing to the nature of
rehabilitation trials, the patients have to meet at the hos-
pital frequently, especially when randomised to the
experimental intervention group.
The trial will, to our knowledge, be the largest trial
conducted that deals with rehabilitation AF ablation reci-
pients. If a positive effect of integrated rehabilitation is
found, it may have an impact on the rehabilitation
offered to patients treated for AF with RFA at the inter-
national level. The trial is expected to identify an inter-
vention which can improve the health and quality of life
of patients, and subsequently reduce healthcare utilisa-
tion and costs, as well as mortality.
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